Exploring New Horizons:A Novel Cdk5 Inhibitor Restoring Cognitive Function and Alleviating Type 2 Diabetes.

A preprint abstract from biorxiv.org discusses the potential of a novel Cdk5 inhibitor in treating type 2 diabetes (T2D) and cognitive decline. T2D is often associated with cognitive decline and is linked to Alzheimer's disease. The researchers identified two brain-penetrant Cdk5 inhibitors, BLINK11 and BLINK15, which showed promise in improving T2D pathogenesis, including blood glucose, obesity, and cognitive impairment. However, it is important to note that this preprint has not yet undergone peer review. [Extracted from the article]